echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Microchip's overseas partner, Huya Biotechnology, announces that chidamine monotherapy has been approved in Japan for the treatment of peripheral T-cell lymphoma

    Microchip's overseas partner, Huya Biotechnology, announces that chidamine monotherapy has been approved in Japan for the treatment of peripheral T-cell lymphoma

    • Last Update: 2022-01-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>


    The approval of the PTCL indication is based on data from a Phase 2b study of 55 aggressive PTCL patients from Japan and South Korea


    Dr.


    Dr.


    Dr.


    About Chidamide

    Chidamide is a new molecular entity drug with global patent protection discovered exclusively by Microchip Biosciences.


    Chidamide has obtained invention patents in nearly 30 countries and regions around the world.


    About Microchip

    Microchip Bio is a modern biomedical company founded in 2001 by a senior team returning from the United States


    Relying on the self-created internationally advanced "integrated drug discovery and early evaluation platform based on chemical genomics", Microchip Biosciences has been involved in five major diseases including tumors, metabolic diseases, autoimmune diseases, central nervous diseases and antiviral diseases.


    At present, Microchip has a wholly-owned subsidiary of Shenzhen Headquarters/R&D Center/GMP production base, Shenzhen Chips Pharmaceutical Co.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.